Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Phase 1

Completed

• Conditions: Tumors
• Interventions: Drug: Anti-angiogenesis; Drug: AMG 706

• Registration Number: NCT00093873
• Lead Sponsor: Amgen

Brief Summary

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Study First Submitted: 2004-10-06
• Study First Submitted QC: 2004-10-07
• Study First Posted: 2004-10-08
• Primary Completion: 2006-02
• Study Completion: 2006-12
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-13
• Last Update Posted: 2013-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AMG 706	Anti-angiogenesis	AMG 706 QD
AMG 706	AMG 706	AMG 706 QD

Primary Outcome Measures

Name	Time	Method
Dose limiting toxicity	Cycle 1

Secondary Outcome Measures

Name	Time	Method
Dose selection	Study completion